Technical Analysis for LRMR - Larimar Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
180 Bearish Setup | Bearish Swing Setup | 0.00% | |
Slingshot Bearish | Bearish Swing Setup | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Lower Bollinger Band Walk | Weakness | -4.70% | |
Wide Bands | Range Expansion | -4.70% | |
Lower Bollinger Band Touch | Weakness | -4.70% | |
Oversold Stochastic | Weakness | -4.70% |
Alert | Time |
---|---|
Fell Below Lower Bollinger Band | about 17 hours ago |
Down 5% | about 18 hours ago |
Lower Bollinger Band Support | about 21 hours ago |
60 Minute Opening Range Breakdown | about 22 hours ago |
Down 3% | about 22 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Drug Discovery Rare Diseases Genetic Diseases Progressive Clinical Pharmacology Fusion Protein Ataxia Friedreich's Ataxia Trinucleotide Repeat Disorders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Drug Discovery Rare Diseases Genetic Diseases Progressive Clinical Pharmacology Fusion Protein Ataxia Friedreich's Ataxia Trinucleotide Repeat Disorders
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.68 |
52 Week Low | 3.19 |
Average Volume | 747,655 |
200-Day Moving Average | 8.13 |
50-Day Moving Average | 7.29 |
20-Day Moving Average | 7.82 |
10-Day Moving Average | 7.72 |
Average True Range | 0.67 |
RSI (14) | 36.31 |
ADX | 25.71 |
+DI | 21.82 |
-DI | 32.49 |
Chandelier Exit (Long, 3 ATRs) | 7.49 |
Chandelier Exit (Short, 3 ATRs) | 7.93 |
Upper Bollinger Bands | 9.66 |
Lower Bollinger Band | 5.99 |
Percent B (%b) | 0.02 |
BandWidth | 46.89 |
MACD Line | -0.23 |
MACD Signal Line | 0.07 |
MACD Histogram | -0.3021 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 7.07 | ||||
Resistance 3 (R3) | 7.13 | 6.87 | 6.91 | ||
Resistance 2 (R2) | 6.87 | 6.61 | 6.84 | 6.85 | |
Resistance 1 (R1) | 6.47 | 6.46 | 6.34 | 6.41 | 6.79 |
Pivot Point | 6.21 | 6.21 | 6.14 | 6.18 | 6.21 |
Support 1 (S1) | 5.81 | 5.95 | 5.68 | 5.75 | 5.37 |
Support 2 (S2) | 5.55 | 5.80 | 5.52 | 5.31 | |
Support 3 (S3) | 5.15 | 5.55 | 5.26 | ||
Support 4 (S4) | 5.09 |